Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Podoplanin (pdpn)

  • Niharika Swain
  • Samapika Routray
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101933

Synonyms

Historical Background

Podoplanin (PDPN) is a mucin-type transmembrane protein (36–43 kDa) having homologous in various species including humans, mice, rats, dogs, and hamsters and also well conserved between them. Since its discovery in 1990, several homologous proteins of PDPN were identified and described in different tissues, i.e., as E11 in lymphatic endothelial cells, gp38 in fibroblastic reticular cells of lymphoid organs and thymic epithelial cells, T1α/rTI40in alveolar type 1 epithelial cells, PA2.26 in skin keratinocytes upon injury, OTS-8 in induced osteoblasts, and as Aggrus, a platelet-aggregating factor. In 1997, finally this molecule was named as podoplanin by Breiteneder-Geleff et al. due to its expression in developing glomeruli in rat kidney and its potential role in flattening of foot...

This is a preview of subscription content, log in to check access.

References

  1. Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol. 2012;3:283. doi:10.3389/fimmu.2012.00283.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, Ochiai A. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun. 2008;373(1):36–41.CrossRefPubMedGoogle Scholar
  3. Caetano AS, Tjioe KC, Faustino SES, Hanemann JAC, Belone AFF, Soares CT, Oliveira DT. Immunolocalization of podoplanin in benign odontogenic tumours with and without ectomesenchyme. Arch Oral Biol. 2013;58(4):408–15.CrossRefGoogle Scholar
  4. Fernández-Muñoz B, Yurrita MM, Martín-Villar E, Carrasco-Ramírez P, Megías D, Renart J, Quintanilla M. The transmembrane domain of podoplanin is required for its association with lipid rafts and the induction of epithelial-mesenchymal transition. Int J Biochem Cell Biol. 2011;43(6):886–96. doi:10.1016/j.biocel.2011.02.010.CrossRefPubMedGoogle Scholar
  5. Krishnan H, Ochoa-Alvarez JA, Shen Y, Nevel E, Lakshminarayanan M, Williams MC, Ramirez MI, Miller WT, Goldberg GS. J Biol Chem. 2013;288(17):12215–21.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Hata M, Ueki T, Sato A, Kojima H, Sawa Y. Expression of podoplanin in the mouse salivary glands. Arch Oral Biol. 2008;53(9):835–41.CrossRefPubMedGoogle Scholar
  7. Nakazawa Y, Sato S, Naito M, Kato Y, Mishima K, Arai H, Tsuruo T, Fujita N. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood. 2008;112:1730–9.CrossRefPubMedGoogle Scholar
  8. Ohta M, Abe A, Ohno F, et al. Positive and negative regulation of podoplanin expression by TGF-β and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines. Oral Oncol. 2013;49(1):20–6. doi:10.1016/j.oraloncology.2012.06.017.CrossRefPubMedGoogle Scholar
  9. Okamoto E, Kikuchi K, Miyazaki Y, González-Alva P, Oku Y, Tanaka A, Yoshida N, Fujinami M, Ide F, Sakashita H, Kusama K. Significance of podoplanin expression in keratocystic odontogenic tumor. J Oral Pathol Med. 2010;39:110–4. doi:10.1111/j.1600-0714.2009.00851.CrossRefPubMedGoogle Scholar
  10. Pan Y, Wang WD, Yago T. Transcriptional regulation of podoplanin expression by Prox1 in lymphatic endothelial cells. Microvasc Res. 2014;94:96–102. doi:10.1016/j.mvr.2014.05.006.CrossRefPubMedGoogle Scholar
  11. Renart J, Carrasco-Ramirez P, Fernandez-Munoz B, Martin-Villar E, Montero L, Yurrita MM, Quintanilla M. New insights into the role of podoplanin in epithelial-mesenchymal transition. In: Jeon KW, editor. International review of cell and molecular biology. San Diego: Academic; 2015. p. 189–90.Google Scholar
  12. Rodrigo JP, García-Carracedo D, González MV, Mancebo G, Fresno MF, García-Pedrero J. Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas. Mol Cancer. 2010;9:48. doi:10.1186/1476-4598-9-48.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong Y-K, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166(3):913–21.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Swain N, Kumar S, Routray S, Pathak J, Patel S. Podoplanin – a novel marker in oral carcinogenesis. Tumour Biol. 2014;35(9):8407–13.CrossRefPubMedGoogle Scholar
  15. Tsuneki M, Maruyama S, Yamazaki M, Essa A, Abé T, Babkair HA, Ahsan MS, Cheng J, Saku T. Podoplanin is a novel myoepithelial cell marker in pleomorphic adenoma and other salivary gland tumors with myoepithelial differentiation. Virchows Arch. 2013;462:297.CrossRefPubMedGoogle Scholar
  16. Ugorski M, Dziegiel P, Suchanski J. Podoplanin – a small glycoprotein with many faces. Am J Cancer Res. 2016;6(2):370–86.PubMedPubMedCentralGoogle Scholar
  17. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer. 2007;96:1–5. doi:10.1038/sj.bjc.6603518.CrossRefPubMedGoogle Scholar
  18. Wu HM, Ren GX, Wang LZ, ZhangY CWT, Guo W. Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes. Mol Med Rep. 2012;6(2):271–4. doi:10.3892/mmr.2012.911.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.MGM Dental College and HospitalNavi MumbaiIndia
  2. 2.Department of Dental SurgeryAll India Institute of Medical SciencesBhubaneswarIndia